335 related articles for article (PubMed ID: 22305847)
1. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study.
Dubin R; Li Y; Ix JH; Shlipak MG; Whooley M; Peralta CA
Am Heart J; 2012 Feb; 163(2):274-9. PubMed ID: 22305847
[TBL] [Abstract][Full Text] [Related]
2. Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.
Jenny NS; Blumenthal RS; Kronmal RA; Rotter JI; Siscovick DS; Psaty BM
J Thromb Haemost; 2014 Jun; 12(6):999-1005. PubMed ID: 24628740
[TBL] [Abstract][Full Text] [Related]
3. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.
Ix JH; Shlipak MG; Chertow GM; Whooley MA
Circulation; 2007 Jan; 115(2):173-9. PubMed ID: 17190862
[TBL] [Abstract][Full Text] [Related]
4. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.
Latini R; Gullestad L; Masson S; Nymo SH; Ueland T; Cuccovillo I; Vårdal M; Bottazzi B; Mantovani A; Lucci D; Masuda N; Sudo Y; Wikstrand J; Tognoni G; Aukrust P; Tavazzi L;
Eur J Heart Fail; 2012 Sep; 14(9):992-9. PubMed ID: 22740508
[TBL] [Abstract][Full Text] [Related]
5. Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly.
Sjöberg B; Qureshi AR; Heimbürger O; Stenvinkel P; Lind L; Larsson A; Bárány P; Ärnlöv J
J Intern Med; 2016 Feb; 279(2):173-9. PubMed ID: 26355706
[TBL] [Abstract][Full Text] [Related]
6. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.
Jia X; Sun W; Hoogeveen RC; Nambi V; Matsushita K; Folsom AR; Heiss G; Couper DJ; Solomon SD; Boerwinkle E; Shah A; Selvin E; de Lemos JA; Ballantyne CM
Circulation; 2019 Jun; 139(23):2642-2653. PubMed ID: 31030544
[TBL] [Abstract][Full Text] [Related]
7. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction.
Matsubara J; Sugiyama S; Nozaki T; Akiyama E; Matsuzawa Y; Kurokawa H; Maeda H; Fujisue K; Sugamura K; Yamamoto E; Matsui K; Jinnouchi H; Ogawa H
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25012287
[TBL] [Abstract][Full Text] [Related]
8. Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis.
Dubin R; Shlipak M; Li Y; Ix J; de Boer IH; Jenny N; Peralta CA
Nephrol Dial Transplant; 2011 Jun; 26(6):1903-8. PubMed ID: 21079193
[TBL] [Abstract][Full Text] [Related]
9. Relation of obesity to heart failure hospitalization and cardiovascular events in persons with stable coronary heart disease (from the Heart and Soul Study).
Spies C; Farzaneh-Far R; Na B; Kanaya A; Schiller NB; Whooley MA
Am J Cardiol; 2009 Oct; 104(7):883-9. PubMed ID: 19766751
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease.
Fluschnik N; Ojeda F; Zeller T; Jørgensen T; Kuulasmaa K; Becher PM; Sinning C; Blankenberg S; Westermann D
PLoS One; 2018; 13(5):e0197497. PubMed ID: 29771963
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.
Latini R; Maggioni AP; Peri G; Gonzini L; Lucci D; Mocarelli P; Vago L; Pasqualini F; Signorini S; Soldateschi D; Tarli L; Schweiger C; Fresco C; Cecere R; Tognoni G; Mantovani A;
Circulation; 2004 Oct; 110(16):2349-54. PubMed ID: 15477419
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study.
Lutsey PL; Alonso A; Selvin E; Pankow JS; Michos ED; Agarwal SK; Loehr LR; Eckfeldt JH; Coresh J
J Am Heart Assoc; 2014 Jun; 3(3):e000936. PubMed ID: 24922628
[TBL] [Abstract][Full Text] [Related]
13. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study.
Jenny NS; Arnold AM; Kuller LH; Tracy RP; Psaty BM
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):594-9. PubMed ID: 19164811
[TBL] [Abstract][Full Text] [Related]
14. Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study.
Beatty AL; Ku IA; Bibbins-Domingo K; Christenson RH; DeFilippi CR; Ganz P; Ix JH; Lloyd-Jones D; Omland T; Sabatine MS; Schiller NB; Shlipak MG; Skali H; Takeuchi M; Vittinghoff E; Whooley MA
J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26150476
[TBL] [Abstract][Full Text] [Related]
15. Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome.
Mjelva ØR; Pönitz V; Brügger-Andersen T; Grundt H; Staines H; Nilsen DW
Eur J Prev Cardiol; 2016 Jul; 23(11):1130-40. PubMed ID: 26635361
[TBL] [Abstract][Full Text] [Related]
16. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study.
Tsui JI; Whooley MA; Monto A; Seal K; Tien PC; Shlipak M
J Card Fail; 2009 Jun; 15(5):451-6. PubMed ID: 19477406
[TBL] [Abstract][Full Text] [Related]
17. Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study.
Garimella PS; Katz R; Patel KV; Kritchevsky SB; Parikh CR; Ix JH; Fried LF; Newman AB; Shlipak MG; Harris TB; Sarnak MJ;
Circ Heart Fail; 2016 Jan; 9(1):e002124. PubMed ID: 26721912
[TBL] [Abstract][Full Text] [Related]
18. Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study.
Park M; Vittinghoff E; Shlipak MG; Mishra R; Whooley M; Bansal N
Am Heart J; 2014 Dec; 168(6):931-9.e2. PubMed ID: 25458658
[TBL] [Abstract][Full Text] [Related]
19. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.
Suzuki S; Takeishi Y; Niizeki T; Koyama Y; Kitahara T; Sasaki T; Sagara M; Kubota I
Am Heart J; 2008 Jan; 155(1):75-81. PubMed ID: 18082493
[TBL] [Abstract][Full Text] [Related]
20. Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study.
Zhao D; Guallar E; Vaidya D; Ndumele CE; Ouyang P; Post WS; Lima JA; Ying W; Kass DA; Hoogeveen RC; Shah SJ; Subramanya V; Michos ED
J Am Heart Assoc; 2020 Jan; 9(2):e013966. PubMed ID: 31928156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
